These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 37537665)

  • 1. Systems analysis and improvement approach to improve naloxone distribution within syringe service programs: study protocol of a randomized controlled trial.
    Akiba CF; Patel SV; Wenger LD; Morgan-Lopez A; Zarkin GA; Orme S; Davidson PJ; Kral AH; Lambdin BH
    Implement Sci; 2023 Aug; 18(1):33. PubMed ID: 37537665
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimizing naloxone distribution to prevent opioid overdose fatalities: results from piloting the Systems Analysis and Improvement Approach within syringe service programs.
    Patel SV; Wenger LD; Kral AH; Sherr K; Wagner AD; Davidson PJ; Lambdin BH
    BMC Health Serv Res; 2023 Mar; 23(1):278. PubMed ID: 36949494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Costs of opioid overdose education and naloxone distribution in New York City.
    Behrends CN; Gutkind S; Winkelstein E; Wright M; Dolatshahi J; Welch A; Paone D; Kunins HV; Schackman BR
    Subst Abus; 2022; 43(1):692-698. PubMed ID: 34666633
    [No Abstract]   [Full Text] [Related]  

  • 4. How do contextual factors influence naloxone distribution from syringe service programs in the USA: a cross-sectional study.
    Lambdin BH; Wenger L; Bluthenthal R; Bartholomew TS; Tookes HE; LaKosky P; O'Neill S; Kral AH
    Harm Reduct J; 2023 Feb; 20(1):26. PubMed ID: 36855181
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A systematic review of the distribution of take-home naloxone in low- and middle-income countries and barriers to the implementation of take-home naloxone programs.
    Sajwani HS; Williams AV
    Harm Reduct J; 2022 Oct; 19(1):117. PubMed ID: 36266701
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Naloxone's role in the national opioid crisis-past struggles, current efforts, and future opportunities.
    Bennett AS; Elliott L
    Transl Res; 2021 Aug; 234():43-57. PubMed ID: 33684591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluating disparities in prescribing of naloxone after emergency department treatment of opioid overdose.
    Weiner SG; Carroll AD; Brisbon NM; Rodriguez CP; Covahey C; Stringfellow EJ; DiGennaro C; Jalali MS; Wakeman SE
    J Subst Abuse Treat; 2022 Aug; 139():108785. PubMed ID: 35537918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overdose Education and Naloxone Distribution Within Syringe Service Programs - United States, 2019.
    Lambdin BH; Bluthenthal RN; Wenger LD; Wheeler E; Garner B; Lakosky P; Kral AH
    MMWR Morb Mortal Wkly Rep; 2020 Aug; 69(33):1117-1121. PubMed ID: 32817603
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Responding to a surge in overdose deaths: perspectives from US syringe services programs.
    Frost MC; Austin EJ; Corcorran MA; Briggs ES; Behrends CN; Juarez AM; Frank ND; Healy E; Prohaska SM; LaKosky PA; Kapadia SN; Perlman DC; Schackman BR; Des Jarlais DC; Williams EC; Glick SN
    Harm Reduct J; 2022 Jul; 19(1):79. PubMed ID: 35854351
    [TBL] [Abstract][Full Text] [Related]  

  • 10. "That's why we're speaking up today": exploring barriers to overdose fatality prevention in Indianapolis' Black community with semi-structured interviews.
    Seo DC; Satterfield N; Alba-Lopez L; Lee SH; Crabtree C; Cochran N
    Harm Reduct J; 2023 Oct; 20(1):159. PubMed ID: 37891632
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Best practices for community-based overdose education and naloxone distribution programs: results from using the Delphi approach.
    Wenger LD; Doe-Simkins M; Wheeler E; Ongais L; Morris T; Bluthenthal RN; Kral AH; Lambdin BH
    Harm Reduct J; 2022 May; 19(1):55. PubMed ID: 35643444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rates and Costs of Dispensing Naloxone to Patients at High Risk for Opioid Overdose in the United States, 2014-2018.
    Barenie RE; Gagne JJ; Kesselheim AS; Pawar A; Tong A; Luo J; Bateman BT
    Drug Saf; 2020 Jul; 43(7):669-675. PubMed ID: 32180134
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Providers' perceptions on barriers and facilitators to prescribing naloxone for patients at risk for opioid overdose after implementation of a national academic detailing program: A qualitative assessment.
    Bounthavong M; Suh K; Christopher MLD; Veenstra DL; Basu A; Devine EB
    Res Social Adm Pharm; 2020 Aug; 16(8):1033-1040. PubMed ID: 31706950
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Community-based naloxone coverage equity for the prevention of opioid overdose fatalities in racial/ethnic minority communities in Massachusetts and Rhode Island.
    Nolen S; Zang X; Chatterjee A; Behrends CN; Green TC; Kumar A; Linas BP; Morgan JR; Murphy SM; Walley AY; Yan S; Schackman BR; Marshall BDL
    Addiction; 2022 May; 117(5):1372-1381. PubMed ID: 34825427
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterizing and combating the opioid epidemic in the Los Angeles County jail system.
    Tran NT; Muradian IK; Qureshi N; Singh J; Henderson SO
    J Subst Use Addict Treat; 2023 Apr; 147():208984. PubMed ID: 36841073
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting community-based naloxone distribution using opioid overdose death rates: A descriptive analysis of naloxone rescue kits and opioid overdose deaths in Massachusetts and Rhode Island.
    Zang X; Macmadu A; Krieger MS; Behrends CN; Green TC; Morgan JR; Murphy SM; Nolen S; Walley AY; Schackman BR; Marshall BD
    Int J Drug Policy; 2021 Dec; 98():103435. PubMed ID: 34482264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Barriers to and recommendations for take-home naloxone distribution: perspectives from opioid treatment programs in New Mexico.
    Salvador JG; Sussman AL; Takeda MY; Katzman WG; Moya Balasch M; Katzman JG
    Harm Reduct J; 2020 May; 17(1):31. PubMed ID: 32404109
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Study protocol for the Respond to Prevent Study: a multi-state randomized controlled trial to improve provision of naloxone, buprenorphine and nonprescription syringes in community pharmacies.
    Green TC; Bratberg J; Irwin AN; Boggis J; Gray M; Leichtling G; Bolivar D; Floyd A; Al-Jammali Z; Arnold J; Hansen R; Hartung D
    Subst Abus; 2022; 43(1):901-905. PubMed ID: 35213293
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Urgent need to expand syringe services programs in South Carolina and beyond.
    Pham Q; Burrows M; Litwin A
    Subst Abuse Treat Prev Policy; 2022 Jun; 17(1):47. PubMed ID: 35729624
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Take-home naloxone programs for suspected opioid overdose in community settings: a scoping umbrella review.
    Moustaqim-Barrette A; Dhillon D; Ng J; Sundvick K; Ali F; Elton-Marshall T; Leece P; Rittenbach K; Ferguson M; Buxton JA
    BMC Public Health; 2021 Mar; 21(1):597. PubMed ID: 33771150
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.